Structural characterization of Posaconazole- parechovirus A3 capsid interaction using molecular simulations and cell infection assays

Parechovirus-A3 (PeV-A3) is a major cause of central nervous system infections in neonates, associated with meningoencephalitis and neurodevelopmental delays. Yet there are no specific antivirals against PeV-A3 infection. A newer clade of PeV-A3 has emerged post COVID-19, and our preliminary data shows that infants are not immune to the emerging variants, underscoring the need for a focused therapeutic discovery. Posaconazole (POS) is seen to attenuate PeV-A3 entry and infection, but the mechanistic understanding of drug-capsid interaction remains unknown. To this end, we combined mechanistic interrogation of drug-capsid interactions and conformational dynamics, with experimental infection assays. We identify two POS binding sites: a VP0-VP1 interface in the 2009 isolate (US WI-09), and a VP3-VP1 groove in the 2022 isolate (9C-CMKC) and a laboratory-selected POS-resistant variant (US WI-09 POSA P14). Apo simulations showed congruent trajectories of POS: to the VP0 face in US WI-09, and to the VP3 arm in 9C-CMKC and US WI-09 POSA P14. The relative contribution of VP0 to the drug-capsid interaction decreased from 86% in US WI-09 to zero in both 9C-CMKC and US WI-09 POSA P14, indicating a redistribution of binding interactions across capsid subunits. Cysteine or arginine substitutions to VP1 Tyr224 abolished the Tyr224-VP3 anchor. Functionally, 0.3 µM POS inhibited replication of US WI-09 and 9C-CMKC in Vero-P cells but only US WI-09 in receptor-overexpressing Vero-MYADM cells. These findings suggest that POS efficacy depends on binding-site localization near the MYADM-engaging VP0 interface, revealing how emerging PeV-A3 variants may retain drug binding while evading antiviral inhibition.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-13
DOI
https://doi.org/10.64898/2026.11.11.765989
Primary Topic
Viral Infections and Immunology Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Structural characterization of Posaconazole- parechovirus A3 capsid interaction using molecular simulations and cell infection assays

Rahil Salehi, Rangaraj Selvarangan, Debarpan Dhar, Ratul Chowdhury
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Viral Infections and Immunology Research
preprint

Structural characterization of Posaconazole- parechovirus A3 capsid interaction using molecular simulations and cell infection assays

Rahil Salehi, Rangaraj Selvarangan, Debarpan Dhar, Ratul Chowdhury
preprint en

Abstract

Parechovirus-A3 (PeV-A3) is a major cause of central nervous system infections in neonates, associated with meningoencephalitis and neurodevelopmental delays. Yet there are no specific antivirals against PeV-A3 infection. A newer clade of PeV-A3 has emerged post COVID-19, and our preliminary data shows that infants are not immune to the emerging variants, underscoring the need for a focused therapeutic discovery. Posaconazole (POS) is seen to attenuate PeV-A3 entry and infection, but the mechanistic understanding of drug-capsid interaction remains unknown. To this end, we combined mechanistic interrogation of drug-capsid interactions and conformational dynamics, with experimental infection assays. We identify two POS binding sites: a VP0-VP1 interface in the 2009 isolate (US WI-09), and a VP3-VP1 groove in the 2022 isolate (9C-CMKC) and a laboratory-selected POS-resistant variant (US WI-09 POSA P14). Apo simulations showed congruent trajectories of POS: to the VP0 face in US WI-09, and to the VP3 arm in 9C-CMKC and US WI-09 POSA P14. The relative contribution of VP0 to the drug-capsid interaction decreased from 86% in US WI-09 to zero in both 9C-CMKC and US WI-09 POSA P14, indicating a redistribution of binding interactions across capsid subunits. Cysteine or arginine substitutions to VP1 Tyr224 abolished the Tyr224-VP3 anchor. Functionally, 0.3 µM POS inhibited replication of US WI-09 and 9C-CMKC in Vero-P cells but only US WI-09 in receptor-overexpressing Vero-MYADM cells. These findings suggest that POS efficacy depends on binding-site localization near the MYADM-engaging VP0 interface, revealing how emerging PeV-A3 variants may retain drug binding while evading antiviral inhibition.

bioRxiv (Cold Spring Harbor Laboratory)
Iowa State University (US), Children’s Mercy Research Institute (US), Mercy Research (US)
National Science Foundation, Centers for Disease Control and Prevention, University of North Carolina at Chapel Hill, Office of Experimental Program to Stimulate Competitive Research
Good health and well-being
Viral Infections and Immunology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon